Signatera™ has significant predictive value for long-term patient outcomes
The only significant risk factor in stage II-III colorectal cancer5‑8
In multivariate statistical analysis, MRD status as measured by Signatera™ was the only significant predictor of long-term cancer patient outcomes, after adjusting for all known clinicopathological risk factors including disease stage and lymph node status.1
When to use Signatera™ MRD test?
- Use after to surgery to evaluate the need for adjuvant chemotherapy
- To personalize and help inform when to escalate or right-size treatment
- Detect MRD with greater sensitivity than current standard of care tools
- Use Signatera™ alongside CEA to detect relapse earlier and reduce false positive CEA results
Lajos Pusztai, MD, DPhil
Professor of Medicine (Medical Oncology); Co-Leader, Genetics, Genomics and Epigenetics Research Program, Yale Cancer Center, Yale School of Medicine
Signatera™ can help guide care for your cancer patients
|Risk level||Actionable results: Stage II-III Colorectal||Test Interpretation|
|ctDNA High Risk||Consider directed imaging (PET/MRI) to locate the disease while potentially resectable||>97% of patients will relapse|
|ctDNA Reduced Risk||Continue monitoring with reassurance||12-14% patients may relapse. Patients who remain negative 2 years post treatment have risk reduced to 3%|
Do your patients qualify for the BESPOKE CRC trial?
Our prospective, multicenter study examines the clinical utility of the Signatera™ ctDNA test for monitoring recurrence and guiding treatment decisions in patients with solid tumors. Find out if your patients qualify for the BESPOKE clinical trial.